Abliva's lead clinical programme, KL1333, aimed at treating primary mitochondrial disorders, made significant advancements during Q2. The completion of a phase Ia/b study, and a second study examining the effects of KL1333 when administered together with common therapeutics, were key steps towards a phase II/III study start expected in late 2021. BioStock reached out to CEO Ellen Donnelly for a comment.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se